Dr. Reddy’s Mexico API plant gets two USFDA observations after records assessment
Reuters2026/09/14 10:36Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Dr. Reddy's Laboratories’ Dr. Reddy's Mexico API plant in Jiutepec, Mexico received two USFDA observations following a records assessment.
- Assessment under Section 704(a)(4) ran from July 17, 2026 to Sept. 8, 2026; USFDA issued Form FDA 2953.
- Dr. Reddy's plans to respond to the two observations within the required timeline.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000646), on September 14, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Top Premarket Decliners
MT newswire•2026/09/14 11:44
--GUIDANCE: (NEE) NextEra Expects 2026 Adjusted EPS Range $3.92 - $4.02, vs. FactSet Est of $4.03
MT newswire•2026/09/14 11:43
Piedmont Realty Trust plans USD 200 million exchangeable senior notes offering
Reuters•2026/09/14 11:42
Bamboo Insurance Services Starts Roadshow for Planned IPO of 35 Million Class A Shares
MT newswire•2026/09/14 11:41
